HitGen has established a drug discovery research platform for small molecules and nucleic acid drugs centered on the design, synthesis and screening of DNA encoded chemical libraries (DELs), fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) technologies.
李进 董事长
陆恺 副董事长
李建国 董事
SUIBO LI 董事
王剑明 董事
郭云沛 独立董事
唐国琼 独立董事
薛军福 独立董事
职工代表董事 瞿庆喜